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ABSTRACT
Introduction: The Hedgehog (Hh) signalling pathway is a developmental signalling pathway involved in normal 
mammalian developmental and homeostasis of adult renewable tissues. In most adult tissues, this pathway remains 
silent and previous studies have shown that constitutive activation of Hedgehog signalling pathway leads to various 
types of malignancies including medulloblastomas, basal cell carcinoma, gastrointestinal, breast and prostate cancer. 
The purpose of this study was to investigate the immunohistochemical expression of Hedgehog pathway proteins 
in Diffuse Large B-cell Lymphoma and determine their association with overall survival (OS). Methods: Positive 
control using normal tonsils were included in each batch of immunohistochemical staining procedure. Results: 
PTCH1 proteins were highly expressed in DLBCL and showed strong staining intensity in 107 (100%) cases and 
SMO proteins were expressed in 105 (98.1%) cases. PTCH1 proteins were localised in the nucleus of tumour cells, 
whereas SMO proteins were mainly localised in the cytoplasm of tumour cells. Positive expression of PTCH1 and 
SMO proteins and overall survival of DLBCL patients were correlated with age, gender, race and tumour location. 
There was no significant correlation between the expression of these two proteins with any of the parameters. 
PTCH1 expression showed significant association with SMO expression (P=0.03). Conclusions: Our findings suggest 
that high expression of both PTCH1 and SMO may be important in the pathogenesis of DLBCL. However, additional 
mechanisms that may contribute to the activation of  HH signalling in DLBCL needs to be further explored. 
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INTRODUCTION
DLBCL is the commonest subtype of Non Hodgkin 
Lymphoma. Despite its aggressive behaviour, it remains 
a treatable lymphoma with enhanced result combining 
the use of rituximab in standard regimens (1). According 
to the National Cancer Registry, 2007, lymphoma is 
the 6th commonest cancer among Malaysians. It is the 
sixth most common cancer in males and the eighth most 
common cancer in females (2).  In 2010, the World 
Health Organization (WHO) recorded that lymphoma 
was the 21st top killer disease with 0.97% of the total 
death. Almost one thousand patients are diagnosed 
every day (3). Studies have discovered useful prognostic 
markers with a subsequent deeper understanding 
of the various origins of DLBCL in order to provide 
potential therapeutic intervention (4). The hedgehog 
(HH) signalling pathway is a highly regulated signalling 
pathway that is  important in the pathogenesis of several 
malignancies.  The HH family of proteins comprises 
three ligands, Sonic hedgehog (Shh), Indian hedgehog 
(Ihh) and Desert hedgehog (Dhh)(5). Without the ligand, 
the 12-pass membrane receptor Patched (PTCH) will 
inhibit the action of another transmembrane G-protein-
coupled receptor (GPCR); Smoothened (SMO)(6,7). This 
in return will switch off the pathway and the target gene 
transcription in the nucleus are inactivated. At the point 
when HH ligands binds to PTCH, inhibition of SMO is 
released and a complex signalling cascade is transduced 
to the cytoplasm by the serine/threonine protein kinase 
Fused (Fu), Suppressor of Fused (SuFu) and GLI (8). 
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A number of reports have shown that HH overexpression, 
that is accompanied by an increased in the expression 
of target genes play a role in gastric cancer, pancreatic 
cancer, glioma, breast, small cell lung carcinoma and 
prostate cancer. The initial link between HH signalling 
and human cancers was made from the findings that 
mutations in the HH pathway components PTCH1 was 
associated with a hereditary form of the basal cell nevus 
syndrome (BCNS) or also known as Gorlin syndrome 
(9). Patients with Gorlin syndrome are subject to 
developing advanced basal cell carcinoma (BCC) of the 
skin and are prone to rare tumours, medulloblastoma 
and   rhabdomyosarcoma. Inappropriate activation 
of HH signalling pathway has also been shown in 
hematopoietic malignancies.  
MATERIALS AND METHODS
Patient samples
This study was approved by the Medical Research 
and Ethics Committee, Ministry of Health Malaysia 
and Hospital Kuala Lumpur Research Committee. A 
total of 107 formalin fixed paraffin-embedded (FFPE) 
tissue samples of DLBCL were collected between year 
2008 and 2014 for immunohistochemical assay. All 
tumours were histologically and clinically diagnosed by 
Hospital Kuala Lumpur according to the World Health 
Organization classification. 
Immunohistochemistry Analysis
Immunohistochemistry was performed to examine 
PTCH1 and SMO expression in 107 DLBCL cases. The 
procedures were performed with classical protocols 
as previously described (10). Briefly, the FFPE tissue 
blocks received were serially cut and underwent heat-
induced epitope retrieval in pH6.0 citrate buffer (Dako, 
Carpinteria.CA). Endogenous peroxidase was blocked 
using 3% H2O2 solution for 30 minutes. The following 
primary antibodies were applied: rabbit polyclonal anti-
Ptch1 (1:150, AB53715; Abcam) and rabbit polyclonal 
anti-SMO (1:200, AB134906; Abcam). Incubation of 
appropriately diluted primary antibody for PTCH1 
and SMO were at room temperature for 60 minutes. 
Secondary antibodies with DAKO Envision Kit, K5007, 
were applied for 30 minutes at 24°C. Detection of protein 
was visualized using chromogen diaminobenzine (DAB) 
(Dako, USA) for 5 minutes to develop the brown colour. 
Slides were counterstained lightly with hematoxylin. 
Cases were considered as positive if 10% or more (by 
estimation) of the tumour cells were expressing the 
proteins (11). Protein expression was scored as negative, 
low or high depending on the staining intensity.  Three 
tonsil tissues were used as positive controls for both 
PTCH1 and SMO proteins.
Statistical Analysis
Statistical calculations were performed using the 
standard statistical software package, IBM SPSS Statistics 
for Windows, Version 17.0. Chi square (χ²) test was 
used to evaluate the association between categorical 
variables. Univariate analysis: The Kaplan-Meier and 
the log-rank test were used to estimate overall survival 
distributions. Overall survival (OS) was calculated as the 
time from diagnosis to the date of death or last contact. 
Patients who were alive at last contact were treated 
as censored for OS analysis. In all o f  t he  statistical 
analyses, a p-value of <0.05 (95% confidence interval) 
was considered to be statistically significant.  
RESULTS
Expression of  PTCH1 and SMO proteins in DLBCL 
tissue
A total of 107 cases with DLBCL comprising 65 males 
and 42 females were retrieved. The mean age of male 
patients was 52 years (median: 55; range 3-87 years) and 
56 years for female patients (median: 55; range 17-90 
years). Most of the cases were elderlies of over 55 years 
old, which approximately contribute to 53.3% of the 
total sample. Tumours were mostly located in the lymph 
nodes (n=57. 53.3%). Extranodal involvement includes 
CNS/brain, n=23, skin/soft tissue, n=7, gastrointestinal, 
n=7, head and neck; bone involvement, n=6, and 
genital, n=1 (Table I).  As shown in Table 2, PTCH1 and 
SMO proteins are highly expressed in DLBCL. PTCH1 
protein is overexpressed  in all of 107 DLBCL cases.  19 
cases (17.8%) had low expression, and 88 cases (82.2%) 
had high expression. In positive cases, the expression of 
PTCH1 was observed outlining the cell membrane and 
in the nucleus of malignant cells. SMO was positively 
expressed in 105/107 (98.1%) cases of DLBCL and was 
localized within the cytoplasm of the malignant cells. 
82 cases (76.6%) showed high expression, 23 cases 
(21.5%) showed low expression and only two cases 
(1.9%) showed negative expression. Figure 1 shows 
a H&E stained photomicrograph of normal tonsils 
and DLBCL. Figure 2 shows the photomicrographs of 
immunohistochemical staining in normal tonsils and 
DLBCL tissues. 
Correlation of immunohistochemical expression 
between Hh pathway proteins
The findings in this study showed that there was a 
significant correlation between the expression of PTCH1 
with SMO (P=0.03). Tumour cells that are PTCH1 
positive are more likely to express SMO.  
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Table I
Characteristic No. of cases (%)
PTCH1 SMO
Low 
expression
(%)
High 
expression
(%)
P Negative
(%)
Low 
expression 
(%)
High 
expression
(%)
P
Age
      < 55 50 (46.7) 10 (20) 40 (80) 0.570 2 (4) 9 (18) 39 (78) 0.283
       ≥ 55 57 (53.3) 9 (15.8) 48 (84.2) 0 (0) 14 (24.6) 43 (75.4)
Gender
      Male 65 (60.7) 10 (15.4) 55 (84.6) 0.424 2 (3.1) 10 (15.4) 53 (81.5) 0.082
     Female 42 (39.3) 9 (21.4) 33 (78.6) 0 (0) 13 (31) 29 (69)
Race
     Malay 76 (71) 16 (20.8) 61 (79.2) 0.376 2 (2.6) 16 (20.8) 59 (76.6)
0.468     Chinese 20 (18.7) 1 (5.3) 18 (94.7) 0 (0) 5 (26.3) 14 (73.3)
     India 7 (6.5) 1 (14.3) 6 (85.7) 0 (0) 0 (0) 7 (100)
     Others 4 (3.7) 1 (25) 3 (75) 0 (0) 2 (50) 2 (50)
Tumour Location
     Nodal 57 (53.3) 10 (17.5) 4 7 (82.5) 0.951 2 (3.5) 11 (19.3) 44 (77.2) 0.518
     Extranodal 50 (46.7) 9 (18) 41 (82) 0 (0) 12 (24) 38 (76)
Table 2
Markers P value
PTCH1-SMO 0.030*
*Significant P value <0.05 by chi-square test.
Fig. 1. H & E stained photomicrograph of normal tonsils (x200) and DLBCL (x200)
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Fig. 2. Representative photomicrographs of immunohistochemical staining of (A) PTCH1 expressed in the 
germinal center of normal tonsil (x200)  and (B) strong PTCH1 staining in the nucleus of DLBCL (x200). (C) 
SMO expressed in the germinal center of normal tonsil (x200) and (D) strong SMO staining in the cytoplasm 
of DLBCL (x200). (E) Negative PTCH1 staining in DLBCL (x200). (F) Negative SMO staining in DLBCL (x200)
Expression between HH proteins and their overall 
survival of DLBCL
The mean OS for DLBCL patients in this study was 65 
months with 5-year overall survival of 74%. The overall 
survival curves were plotted against age, gender, race 
and tumour location, however no significant association 
with HH protein expression were shown.
DISCUSSION
Inappropriate activation of the HH signaling pathway 
has been shown in many cancers, including two well-
recognized cancers; BCC and medulloblastoma (12–
14). Modes of the HH signalling pathway in cancer 
development may vary according to tumour types. 
Aberrant HH pathway mechanism appears to be complex 
and can either be in an autocrine and some may favour a 
paracrine model. Report has shown that haematological 
malignancies involved in a reverse paracrine mode 
and has only been observed in hematologic models of 
B-cell lymphoma, multiple myeloma and leukaemia 
(15). Our previous study showed that SHH and GLI1 
were expressed at various levels in DLBCL and a large 
percentage of expression are at low levels (16). In this 
study, DLBCL commonly expressed PTCH1 and SMO 
at a very high levels. It has been shown that HH ligand, 
in a direct and/or indirect manner, upregulates the 
transcription of its own transcriptional effectors. Thus, 
suggesting the presence of positive autocrine loop with 
a positive feedback mechanism (17, 18).  Because 
PTCH1 acts as HH receptor and SMO as the signal 
transducer that sends signals into the cytoplasm to 
activate transcription factor GLI, this might lead to cell 
proliferation and/or differentiation., thus, regulating the 
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transcription of target genes. In addition, the increased 
amount of PTCH1 may bind to SHH and alter ligand 
accessibility for different target cells by endocytosis.
Studies have found that genetically engineered mice 
with PTCH1 and SMO genes have generated more 
definite evidence for the critical role of HH signalling 
in cancer. Even in small cell lung cancer (SCLC) mouse 
model, the expression of oncogenic SmoM2 increases 
the tumour number, whereas SMO knockout reduces 
the tumour number. Therefore, high levels of SMO 
expression in this study might indicate the cause of an 
aberrant activation of HH signalling in DLBCL.   
We reported that to the best of our knowledge, there is 
no study investigating the expression of SMO and PTCH1 
and correlation with clinicopathological parameters and 
overall survival in DLBCL patients. However, Kim et al., 
2009 showed significant correlation between expression 
levels of GLI1 with GLI2 and GLI3 in DLBCL (15).  In 
summary, understanding the role of signalling pathways, 
particularly HH pathway in the development of cancer 
may provide new input and  offer a possible target in 
therapeutic intervention. Among possible therapeutic 
interventions are inactivating mutations of PTCH, 
activating mutations of SMO and gene amplifications or 
gains involving HH ligands, GLI1 and GLI2.  
CONCLUSIONS
In this study, PTCH1 and SMO were strongly expressed 
in DLBCL. These data provide a rationale for further 
investigation of the biological significance of PTCH1 and 
SMO in tumour biology particularly in the pathogenesis 
and progression of DLBCL
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